Dako to Develop Cancer Companion Dx for Bristol-Myers Squibb | GenomeWeb
NEW YORK (GenomeWeb News) – Dako said today that it will collaborate with drug maker Bristol-Myers Squibb to develop clinical diagnostics as companions to cancer therapeutics.
 
The Danish diagnostics firm plans to develop clinical diagnostics that can identify cancer patients who may benefit from drug candidates that Bristol-Myers Squibb has in development.
 
Dako CEO Patrick Dahlen said the tests it develops under the collaboration will be companion products for specific Bristol-Myers Squibb therapeutics.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: nanopore sequencing workflow to detect antibiotic resistance in gut microbes, TSSPlant tool, and more.

Because gene-edited organisms can cross borders, Gizmodo wonders whether there should be an international body to govern their use.

HHS Secretary nominee Tom Price is to go in front of the Senate Committee on Health, Education, Labor and Pensions today, NPR's Morning Edition reports.

Prior to being closed, Theranos' Arizona lab failed an inspection by regulators, according to the Wall Street Journal.